Developer docs
API playgroundTry for free, no card

Search company profiles

Stenocare

Full company profile

uuid003so1r

Namestring
Stenocare
Legal namestring
Stenocare A/S
Websiteurl
stenocare.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Stenocare A/S is a Danish pharmaceutical company founded in 2017 and listed on Nasdaq First North Denmark (ticker: STENO), headquartered in Copenhagen. The company innovates, imports, and distributes prescription-based medical cannabis products — THC oils, CBD oils, THC/CBD combination oils, the high-concentration CBD100 formulation, and, following the November 2025 CannGros acquisition, five flower products. Its flagship ASTRUM 10-10 oil is built on a patented Lymphatic Targeting Technology (LTT) that Stenocare holds worldwide exclusivity to apply in cannabis products; pharmacokinetic studies show 2.6x higher blood uptake and faster time-to-maximum concentration (1 hour vs 2–4 hours) compared with conventional MCT-oil products.

Stenocare sells exclusively through prescription-based pharmacy distribution across seven markets: Denmark, Sweden, Norway, Germany, the UK, Australia, and France (entered 2026 via ICMF and Movianto partnerships). Channel partners include Apotek 1 in Norway, ADREXPharma in Germany, Cannvalate in Australia, and WEECO Pharma (co-branded Germany launch). The company transitioned under its STENOCARE 3.0 strategy from a cultivation-inclusive model to an asset-light innovation and trading company, focusing capital on product development and international expansion.

Revenue is generated through unit sales of approved products to pharmacies and distributors; pricing is not publicly disclosed, though Denmark provides partial reimbursement (up to DKK 20,000 annually). FY2025 net sales reached a record DKK 7.0 million (~107% YoY growth in Q4 2025), with CannGros expected to add DKK 4–6 million in annual revenue from 2026. The company achieved three consecutive quarters of positive EBITDA in 2025 and is targeting full-year profitability in 2026.

Short descriptiontext

Stenocare is a Danish pharmaceutical company that develops, imports, and distributes prescription-based medical cannabis oils and flower products to patients across seven countries, leveraging patented ASTRUM lymphatic targeting technology with 2.6x improved bioavailability.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKirke-værløse, Denmark
HQ citystring
Kirke-værløse
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription medical cannabis, pharmaceutical cannabis oils, cannabinoid drug formulations, medical cannabis distribution, cannabis-based medicines
Industry1 code
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Medical Cannabis Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Cannabis Product Sales
TypeOne Time License
Description

Stenocare generates revenue from the sale of prescription-based medical cannabis oil products (THC, CBD, and combined formulations) and flower products through pharmacies in Denmark, Sweden, Norway, Germany, UK, Australia, and France. Revenue is generated through product sales to pharmacies and distributors.

news.cision.com
2International Market Expansion
TypeOne Time License
Description

Revenue growth driven by geographic expansion into new markets (Germany, Australia, Norway, France) with approved products, leveraging existing product portfolio and new product launches like ASTRUM.

stenocare.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1ASTRUM
Description

Innovative and patented next-generation medical cannabis oil product featuring advanced oil technology designed to enhance cannabinoid bioavailability. Products include ASTRUM 10-10 (10mg/ml THC and 10mg/ml CBD in 30ml bottle).

stenocare.com
+1 more record
Core offering1 text field

Stenocare is a Danish pharmaceutical company that innovates, imports, and distributes prescription-based medical cannabis oil and flower products across Denmark, Sweden, Norway, Germany, the UK, and Australia. The company manufactures and markets THC, CBD, THC/CBD combination, and high-concentration CBD100 oil formulations under the Danish Pilot Programme, plus the proprietary ASTRUM 10-10 product built on patented lymphatic targeting technology with 2.6x improved bioavailability. Following the November 2025 acquisition of CannGros ApS, the portfolio expanded to nine approved products including five flower-based medical cannabis products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 2.6x higher blood uptake of cannabinoids compared to traditional MCT-oil products
+3 more records
Product overview1 text field

Stenocare is a Danish pharmaceutical company that innovates, imports, and distributes prescription-based medical cannabis products. The company operates across Denmark, Sweden, Norway, Germany, UK, and Australia with a portfolio of nine approved products spanning medical cannabis oils and flower products. The core product line includes THC Oil Stenocare (30 mg/mL THC), CBD Oil Stenocare (20 mg/mL CBD), THC/CBD Oil Stenocare (15/24 mg/mL), and CBD100 Oil Stenocare (100 mg/mL CBD) — all approved under Denmark's permanent medical cannabis framework. The company also offers the patented ASTRUM 10-10 Oil product line featuring lymphatic targeting technology that demonstrates 2.6x improved bioavailability compared to traditional MCT-oil formulations, approved in Germany, Australia, and Norway. Following the November 2025 acquisition of CannGros ApS, Stenocare expanded into five flower-based products alongside its oil portfolio. Products are distributed through pharmacies via prescription and are regulated by respective national health authorities including the Danish Medicines Agency, German BfArM, and Australian TGA.

Product and service8 records
1THC Oil Stenocare
CategoryMedical cannabis oil — THC formulation
Description

Prescription-based medical cannabis oil containing 30 mg/mL THC in a 30 mL bottle with oral dosing syringe; approved under the Danish Pilot Programme and listed on the Danish Medicines Agency's list of cannabis products for medical use.

2CBD Oil Stenocare
CategoryMedical cannabis oil — CBD formulation
Description

Prescription-based medical cannabis oil containing 20 mg/mL CBD, approved under the Danish Pilot Programme for treatment of various conditions.

3THC/CBD Oil Stenocare
CategoryMedical cannabis oil — THC/CBD combination
Description

Combination THC/CBD medical cannabis oil containing 15 mg/mL THC and 24 mg/mL CBD, approved under the Danish Pilot Programme; Stenocare is the first and only supplier of this product in Denmark.

4CBD100 Oil Stenocare
CategoryMedical cannabis oil — high-concentration CBD
Description

High-concentration CBD medical cannabis oil containing 100 mg/mL CBD and 5 mg/mL THC, approved December 2024; Stenocare is the only supplier under the Danish Pilot Programme to offer this high-strength CBD oil.

5ASTRUM 10-10 Oil
CategoryMedical cannabis oil — patented LTT-oil technology
Description

Next-generation patented medical cannabis oil using lymphatic targeting technology (LTT-oil) with 10 mg/mL THC and 10 mg/mL CBD in a 30 mL bottle; demonstrates 2.6x higher blood uptake and 1-hour time to maximum concentration compared to traditional MCT-oil products; approved in Australia, Germany, and Norway.

6CannGros Flower Products
CategoryMedical cannabis flower products
Description

Five approved medical cannabis flower products acquired from DanCann Pharma through the November 2025 share exchange, expanding Stenocare's portfolio from oils into flower-based medical cannabis products for the Danish market.

7Balanced 12.5-12.5 Oil (Australia)
CategoryRegional medical cannabis oil — Australia
Description

Medical cannabis oil containing 12.5 mg/mL THC and 12.5 mg/mL CBD, Stenocare's initial product for the Australian market, launched Q4 2022.

8AD 10-10 STENOCARE Extrakt (Germany)
CategoryRegional medical cannabis oil — Germany
Description

Medical cannabis oil product containing 10 mg/mL THC and 10 mg/mL CBD, approved in Germany through the ADREXPharma partnership and eligible for statutory insurance reimbursement.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Strategic partnership for French market entry. ICMF assists with regulatory dossier submission for ASTRUM 10-10 medical cannabis oil product to French National Health Authority (HAS) for reimbursement evaluation. France is transitioning its four-year pilot program into a permanent framework in 2026.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-11
Description

Partnership with France's leading pharmaceutical distributor for nationwide logistics and pharmacy distribution. Movianto handles nationwide distribution of Stenocare products to pharmacies under the partnership.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-27
Description

Strategic partnership to launch premium medical cannabis oils in Germany. First product 'WEECO ASTRUM 10-10 extract' (10mg/ml THC and 10mg/ml CBD in 30ml bottle) scheduled for February 2026 launch. Leverages WEECO's regulatory expertise and established distribution network.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Acquisition of CannGros ApS from DanCann Pharma through share exchange (5 million new Stenocare shares issued). Expands product portfolio into flower-based medical cannabis. DanCann now owns 11.5% of Stenocare following the transaction.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-05-25
Description

German pharmaceutical partner for market entry and regulatory collaboration with BfArM (Federal Institute for Drugs and Medical Devices). Product 'AD 10-10 STENOCARE Extrakt' approved and launched October 2023.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-10-28
Description

Norwegian pharmacy chain and leading distributor partnership. Distribution agreement for medical cannabis oil products in Norway including THC Drops 30mg/mL, CBD Drops 20mg/mL, and Balanced products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-08-24
Description

Australian medical cannabis company partnership for market entry. Provides access to 600+ pharmacies and 3,000 doctors through online clinic platform. Product launched Q4 2022 with Balanced 12.5-12.5 oil product.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Senza Capital (now part of Kanabo Group)
TypeEmerging player
Description

European medical cannabis distributor focused on pharmacy-channel sales across multiple EU markets. Comparable as a smaller-scale European medical cannabis platform.

TypeDirect peer
Description

Berlin-based medical cannabis distributor operating in Germany and other European markets. Closely comparable as a European-focused prescription cannabis oils platform leveraging partner producers and proprietary distribution.

TypeDirect peer
Description

Danish medical cannabis company that previously owned CannGros ApS and now holds ~11.5% of Stenocare. Directly comparable as a Denmark-based player importing and distributing prescription medical cannabis oils and flowers.

TypeBroad incumbent
Description

Large Canadian cannabis producer with established European medical cannabis operations. Comparable as a broad multi-jurisdiction medical cannabis supplier, though at significantly larger scale and with a much broader product portfolio.

TypeEmerging player
Description

Australian medical cannabis distributor providing access to 600+ pharmacies and 3,000 doctors and Stenocare's Australian distribution partner. Comparable in market role (medical cannabis distribution), though Australia-focused.

TypeDirect peer
Description

German vertically integrated medical cannabis producer and distributor supplying pharmacies in Germany. Comparable as a European prescription medical cannabis operator with regulatory approvals and pharmacy-channel distribution.

7Tilray Brands Inc.
TypeBroad incumbent
Description

Global cannabis incumbent with significant medical cannabis operations across Europe, including Germany. Comparable in target market (prescription medical cannabis in Europe) and pharmacy-channel distribution, but at vastly greater scale.

8Orifarm Group
TypeBroad incumbent
Description

Large Danish/European pharmaceutical company with parallel/specialty pharma distribution and product development capabilities. Comparable as a Northern European pharma operator with broad portfolio and regulatory expertise (board member Søren Melsing Frederiksen is VP at Orifarm).

TypeBroad incumbent
Description

Owner of GW Pharma's Epidiolex and broader cannabinoid-derived prescription drug portfolio. Comparable as a prescription cannabinoid pharmaceutical business targeting European and global markets, though at much larger scale with FDA-approved products.

TypeEmerging player
Description

UK medical cannabis clinic and distributor prescribing THC/CBD products to patients via specialist doctors. Comparable in European prescription cannabis model, though with a clinic-led rather than product-led approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stenocare

Medical Cannabis Pharmaceuticalsstenocare.com

Stenocare is a Danish pharmaceutical company that develops, imports, and distributes prescription-based medical cannabis oils and flower products to patients across seven countries, leveraging patented ASTRUM lymphatic targeting technology with 2.6x improved bioavailability.

What Stenocare does

Stenocare A/S is a Danish pharmaceutical company founded in 2017 and listed on Nasdaq First North Denmark (ticker: STENO), headquartered in Copenhagen. The company innovates, imports, and distributes prescription-based medical cannabis products — THC oils, CBD oils, THC/CBD combination oils, the high-concentration CBD100 formulation, and, following the November 2025 CannGros acquisition, five flower products. Its flagship ASTRUM 10-10 oil is built on a patented Lymphatic Targeting Technology (LTT) that Stenocare holds worldwide exclusivity to apply in cannabis products; pharmacokinetic studies show 2.6x higher blood uptake and faster time-to-maximum concentration (1 hour vs 2–4 hours) compared with conventional MCT-oil products.

Stenocare sells exclusively through prescription-based pharmacy distribution across seven markets: Denmark, Sweden, Norway, Germany, the UK, Australia, and France (entered 2026 via ICMF and Movianto partnerships). Channel partners include Apotek 1 in Norway, ADREXPharma in Germany, Cannvalate in Australia, and WEECO Pharma (co-branded Germany launch). The company transitioned under its STENOCARE 3.0 strategy from a cultivation-inclusive model to an asset-light innovation and trading company, focusing capital on product development and international expansion.

Revenue is generated through unit sales of approved products to pharmacies and distributors; pricing is not publicly disclosed, though Denmark provides partial reimbursement (up to DKK 20,000 annually). FY2025 net sales reached a record DKK 7.0 million (~107% YoY growth in Q4 2025), with CannGros expected to add DKK 4–6 million in annual revenue from 2026. The company achieved three consecutive quarters of positive EBITDA in 2025 and is targeting full-year profitability in 2026.

Stenocare firmographics

Firmographics
Name
Stenocare
Legal name
Stenocare A/S
Website
https://stenocare.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Stenocare is a Danish pharmaceutical company that develops, imports, and distributes prescription-based medical cannabis oils and flower products to patients across seven countries, leveraging patented ASTRUM lymphatic targeting technology with 2.6x improved bioavailability.
Ownership category
akta.pro rank

Stenocare industry classification

Industry
Product category
Medical Cannabis Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)

Keywords

  • Prescription medical cannabis
  • Pharmaceutical cannabis oils
  • Cannabinoid drug formulations
  • Medical cannabis distribution
  • Cannabis-based medicines

Where Stenocare is headquartered

Location

Headquarters

HQ city
Kirke-værløse
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Stenocare business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Cannabis Product Sales: Stenocare generates revenue from the sale of prescription-based medical cannabis oil products (THC, CBD, and combined formulations) and flower products through pharmacies in Denmark, Sweden, Norway, Germany, UK, Australia, and France. Revenue is generated through product sales to pharmacies and distributors.
  2. International Market Expansion: Revenue growth driven by geographic expansion into new markets (Germany, Australia, Norway, France) with approved products, leveraging existing product portfolio and new product launches like ASTRUM.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Stenocare product offering

Product offering

Core offering

Stenocare is a Danish pharmaceutical company that innovates, imports, and distributes prescription-based medical cannabis oil and flower products across Denmark, Sweden, Norway, Germany, the UK, and Australia. The company manufactures and markets THC, CBD, THC/CBD combination, and high-concentration CBD100 oil formulations under the Danish Pilot Programme, plus the proprietary ASTRUM 10-10 product built on patented lymphatic targeting technology with 2.6x improved bioavailability. Following the November 2025 acquisition of CannGros ApS, the portfolio expanded to nine approved products including five flower-based medical cannabis products.

Product overview

Stenocare is a Danish pharmaceutical company that innovates, imports, and distributes prescription-based medical cannabis products. The company operates across Denmark, Sweden, Norway, Germany, UK, and Australia with a portfolio of nine approved products spanning medical cannabis oils and flower products. The core product line includes THC Oil Stenocare (30 mg/mL THC), CBD Oil Stenocare (20 mg/mL CBD), THC/CBD Oil Stenocare (15/24 mg/mL), and CBD100 Oil Stenocare (100 mg/mL CBD) — all approved under Denmark's permanent medical cannabis framework. The company also offers the patented ASTRUM 10-10 Oil product line featuring lymphatic targeting technology that demonstrates 2.6x improved bioavailability compared to traditional MCT-oil formulations, approved in Germany, Australia, and Norway. Following the November 2025 acquisition of CannGros ApS, Stenocare expanded into five flower-based products alongside its oil portfolio. Products are distributed through pharmacies via prescription and are regulated by respective national health authorities including the Danish Medicines Agency, German BfArM, and Australian TGA.

Differentiator

Problem solved

Functional benefit

Brands

  • ASTRUM: Innovative and patented next-generation medical cannabis oil product featuring advanced oil technology designed to enhance cannabinoid bioavailability. Products include ASTRUM 10-10 (10mg/ml THC and 10mg/ml CBD in 30ml bottle).
  • STENOCARE 3.0

Products and services

  • THC Oil Stenocare Prescription-based medical cannabis oil containing 30 mg/mL THC in a 30 mL bottle with oral dosing syringe; approved under the Danish Pilot Programme and listed on the Danish Medicines Agency's list of cannabis products for medical use.
  • CBD Oil Stenocare Prescription-based medical cannabis oil containing 20 mg/mL CBD, approved under the Danish Pilot Programme for treatment of various conditions.
  • THC/CBD Oil Stenocare Combination THC/CBD medical cannabis oil containing 15 mg/mL THC and 24 mg/mL CBD, approved under the Danish Pilot Programme; Stenocare is the first and only supplier of this product in Denmark.
  • CBD100 Oil Stenocare High-concentration CBD medical cannabis oil containing 100 mg/mL CBD and 5 mg/mL THC, approved December 2024; Stenocare is the only supplier under the Danish Pilot Programme to offer this high-strength CBD oil.
  • ASTRUM 10-10 Oil Next-generation patented medical cannabis oil using lymphatic targeting technology (LTT-oil) with 10 mg/mL THC and 10 mg/mL CBD in a 30 mL bottle; demonstrates 2.6x higher blood uptake and 1-hour time to maximum concentration compared to traditional MCT-oil products; approved in Australia, Germany, and Norway.
  • CannGros Flower Products Five approved medical cannabis flower products acquired from DanCann Pharma through the November 2025 share exchange, expanding Stenocare's portfolio from oils into flower-based medical cannabis products for the Danish market.
  • Balanced 12.5-12.5 Oil (Australia) Medical cannabis oil containing 12.5 mg/mL THC and 12.5 mg/mL CBD, Stenocare's initial product for the Australian market, launched Q4 2022.
  • AD 10-10 STENOCARE Extrakt (Germany) Medical cannabis oil product containing 10 mg/mL THC and 10 mg/mL CBD, approved in Germany through the ADREXPharma partnership and eligible for statutory insurance reimbursement.

Quantifiable outcome

  • 2.6x higher blood uptake of cannabinoids compared to traditional MCT-oil products
  • +3 more outcomes

Companies that use Stenocare

Customer profile

Segments3 records

Ideal customer profiles3 records

Stenocare technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Stenocare partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • ICMF (Institut des Cannabinoïdes Médicaux Français)coreStrategic or Co-development Partner · 11 February 2026Strategic partnership for French market entry. ICMF assists with regulatory dossier submission for ASTRUM 10-10 medical cannabis oil product to French National Health Authority (HAS) for reimbursement evaluation. France is transitioning its four-year pilot program into a permanent framework in 2026.
  • Movianto (Yusen Logistics Healthcare)coreChannel Partner/ Reseller/ Distributor · 11 February 2026Partnership with France's leading pharmaceutical distributor for nationwide logistics and pharmacy distribution. Movianto handles nationwide distribution of Stenocare products to pharmacies under the partnership.
  • WEECO Pharma GmbHcoreStrategic or Co-development Partner · 27 January 2026Strategic partnership to launch premium medical cannabis oils in Germany. First product 'WEECO ASTRUM 10-10 extract' (10mg/ml THC and 10mg/ml CBD in 30ml bottle) scheduled for February 2026 launch. Leverages WEECO's regulatory expertise and established distribution network.
  • DanCann Pharma A/ScoreStrategic or Co-development Partner · 18 November 2025Acquisition of CannGros ApS from DanCann Pharma through share exchange (5 million new Stenocare shares issued). Expands product portfolio into flower-based medical cannabis. DanCann now owns 11.5% of Stenocare following the transaction.
  • ADREXPharmacoreChannel Partner/ Reseller/ Distributor · 25 May 2023German pharmaceutical partner for market entry and regulatory collaboration with BfArM (Federal Institute for Drugs and Medical Devices). Product 'AD 10-10 STENOCARE Extrakt' approved and launched October 2023.
  • Apotek 1coreChannel Partner/ Reseller/ Distributor · 28 October 2022Norwegian pharmacy chain and leading distributor partnership. Distribution agreement for medical cannabis oil products in Norway including THC Drops 30mg/mL, CBD Drops 20mg/mL, and Balanced products.
  • CannvalatecoreChannel Partner/ Reseller/ Distributor · 24 August 2022Australian medical cannabis company partnership for market entry. Provides access to 600+ pharmacies and 3,000 doctors through online clinic platform. Product launched Q4 2022 with Balanced 12.5-12.5 oil product.

Scale indicators8 records

Recent moves11 records

Expansion highlights6 records

Stenocare competitors and assessment

Company assessment

Emerging players

  • Senza Capital (now part of Kanabo Group): European medical cannabis distributor focused on pharmacy-channel sales across multiple EU markets. Comparable as a smaller-scale European medical cannabis platform.
  • Cannvalate Pty Ltd: Australian medical cannabis distributor providing access to 600+ pharmacies and 3,000 doctors and Stenocare's Australian distribution partner. Comparable in market role (medical cannabis distribution), though Australia-focused.
  • Mamedica: UK medical cannabis clinic and distributor prescribing THC/CBD products to patients via specialist doctors. Comparable in European prescription cannabis model, though with a clinic-led rather than product-led approach.

Direct peers

  • Cantourage Group SE: Berlin-based medical cannabis distributor operating in Germany and other European markets. Closely comparable as a European-focused prescription cannabis oils platform leveraging partner producers and proprietary distribution.
  • DanCann Pharma A/S: Danish medical cannabis company that previously owned CannGros ApS and now holds ~11.5% of Stenocare. Directly comparable as a Denmark-based player importing and distributing prescription medical cannabis oils and flowers.
  • Demecan GmbH: German vertically integrated medical cannabis producer and distributor supplying pharmacies in Germany. Comparable as a European prescription medical cannabis operator with regulatory approvals and pharmacy-channel distribution.

Broad incumbents

  • Aurora Cannabis Inc. Large Canadian cannabis producer with established European medical cannabis operations. Comparable as a broad multi-jurisdiction medical cannabis supplier, though at significantly larger scale and with a much broader product portfolio.
  • Tilray Brands Inc. Global cannabis incumbent with significant medical cannabis operations across Europe, including Germany. Comparable in target market (prescription medical cannabis in Europe) and pharmacy-channel distribution, but at vastly greater scale.
  • Orifarm Group: Large Danish/European pharmaceutical company with parallel/specialty pharma distribution and product development capabilities. Comparable as a Northern European pharma operator with broad portfolio and regulatory expertise (board member Søren Melsing Frederiksen is VP at Orifarm).
  • Jazz Pharmaceuticals plc (GW Pharmaceuticals): Owner of GW Pharma's Epidiolex and broader cannabinoid-derived prescription drug portfolio. Comparable as a prescription cannabinoid pharmaceutical business targeting European and global markets, though at much larger scale with FDA-approved products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

Stenocare social profiles

Digital presence

Stenocare financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stenocare leadership team

Management profile

Number of profiles

Profiles7 records

Stenocare subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Stenocare funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stenocare M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stenocare

What does Stenocare do?

Stenocare is a Danish pharmaceutical company that innovates, imports, and distributes prescription-based medical cannabis oil and flower products across Denmark, Sweden, Norway, Germany, the UK, and Australia. The company manufactures and markets THC, CBD, THC/CBD combination, and high-concentration CBD100 oil formulations under the Danish Pilot Programme, plus the proprietary ASTRUM 10-10 product built on patented lymphatic targeting technology with 2.6x improved bioavailability. Following the November 2025 acquisition of CannGros ApS, the portfolio expanded to nine approved products including five flower-based medical cannabis products.

Is Stenocare a public or private company?

Stenocare is a public company. It is classified as public and is currently operating.

When was Stenocare founded?

Stenocare was founded in 2017. It employs 1 to 10 people.

Where is Stenocare based?

Stenocare is headquartered in Kirke-værløse, Denmark, in the Europe region.

How does Stenocare make money?

Two revenue lines are on record. Medical Cannabis Product Sales are the primary driver. The others are international Market Expansion.

Who are Stenocare's main competitors?

Emerging players on record are Senza Capital (now part of Kanabo Group), Cannvalate Pty Ltd and Mamedica. Direct peers are Cantourage Group SE, DanCann Pharma A/S and Demecan GmbH. Broad incumbents are Aurora Cannabis Inc., Tilray Brands Inc., Orifarm Group and Jazz Pharmaceuticals plc (GW Pharmaceuticals).

Does Stenocare have an API?

No public API is recorded for Stenocare.

What industry is Stenocare in?

Stenocare's product category is Medical Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comSTENOCARE reports first-half results with continued momentum: Q2 sales rise 33% over Q1 with fifth consecutive EBITDA-positive quarterSTENOCARE reported Q2 2026 net sales of DKK 3.99 million, up 33% from Q1, with positive EBITDA of DKK 56 thousand and operating cash flow of DKK 1.56 million. The company completed the CannGros integration and continues preparations for a French medical cannabis programme.news.cision.comCommuniqué from Annual General MeetingSTENOCARE A/S held its annual general meeting on 29 April 2026, where shareholders approved a merger with subsidiary CannGros ApS effective 1 January 2026. The company reported a loss of DKK 2,390,531 for 2025, and all resolutions were adopted unanimously.news.cision.comNotice to Annual General Meeting in STENOCARE A/SThe board of directors of STENOCARE A/S has convened the Annual General Meeting for April 29, 2026, to address standard agenda items including adoption of the audited annual report showing a loss of DKK 2,390,441 for the year. Key proposals include amending the Articles of Association to allow warrant allocations to board members, management, and founders, and merging the 100% owned subsidiary CannGros ApS into Stenocare A/S effective January 1, 2026, to create a leaner and more cost-effective organization. The meeting will also address the re-election of current board members and re-appointment of auditors.news.cision.comSTENOCARE A/S publishes Annual Report 2025STENOCARE A/S published its annual report for fiscal year 2025, declaring it the company's best year ever with record net sales of 7.0 mDKK and positive EBITDA achieved in the final three quarters, though full-year EBITDA remained negative at -1.7 mDKK, a significant improvement from -11.2 mDKK in 2024. The company completed a capital raise of 7.9 mDKK in January 2025 and acquired 100% of CannGros ApS in November 2025 through a share exchange transaction valued at 7.4 mDKK. Looking ahead, STENOCARE expects to achieve profitability in 2026, supported by an expanded product portfolio with nine approved products across Denmark, Germany, Australia, and Norway.news.cision.comInterim report fourth quarter and Financial Statement Release 2025STENOCARE A/S released its Q4 and full-year 2025 financial results, reporting net sales of 7,021 KDKK for the full year and achieving three consecutive quarters of positive EBITDA with Q4 EBITDA of 12 KDKK. The company completed the acquisition of CannGros ApS in November 2025, adding an estimated DKK 4-6 million in annual revenue, and subsequently announced strategic partnerships with WEECO Pharma for product launch in Germany and a distribution partnership in France. Sales for Q4 2025 grew 36% over Q3 2025 and 107% compared to Q4 2024, while personnel expenses decreased 37% year-over-year.Business of CannabisStenocare Launches into France Amid Danish ConsolidationStenocare, a Danish medical cannabis company listed on Nasdaq First North, announced this week its entry into the French market through a partnership with ICMF to submit its ASTRUM 10-10 oil product to France's HAS for reimbursement evaluation, as France transitions its four-year pilot program into a permanent framework that notably excludes flower products. The company completed the acquisition of Danish flower competitor CannGros from DanCann Pharma in November 2025 via a share-for-share exchange, gaining five approved flower products without employees, debt, or operational commitments, and subsequently raised flower prices by approximately 45%, consolidating its dominant position in Denmark's medical cannabis market across both product categories.news.cision.comSTENOCARE A/S positions for First-Mover Advantage in France With Strategic Partnership, Product Filing, and National Distribution PartnershipSTENOCARE A/S has entered a strategic partnership with ICMF (Institut des Cannabinoïdes Médicaux Français) and submitted a regulatory dossier for its ASTRUM 10-10 medical cannabis oil product to the French National Health Authority (HAS) for evaluation of potential reimbursement ahead of France's expected permanent legalization of medical cannabis in 2026. Movianto, a Yusen Logistics Healthcare company and France's leading pharmaceutical distributor, will handle nationwide logistics and pharmacy distribution under the partnership. Independent analysts estimate approximately 300,000 French patients could eventually qualify for treatment under a permanent national framework, subject to HAS approval and reimbursement criteria.AnalystgroupComment on STENOCAREs partnership with WEECO and Launch of a New Astrum Oil Product in GermanySTENOCARE A/S announced a strategic partnership with WEECO Pharma GmbH to launch premium medical cannabis oils in Germany, with the first product "WEECO ASTRUM 10-10 extract" (containing 10mg/ml THC and 10mg/ml CBD in a 30ml bottle) scheduled to be available for patients in February 2026. The collaboration leverages WEECO's regulatory expertise and established distribution network in the German market to accelerate commercialization of STENOCARE's Astrum oil product. Germany represents one of the largest medical cannabis markets in Europe, making this partnership a key value driver for STENOCARE's growth strategy in the coming years.AnalystgroupComment on STENOCARE’s Q2-report 2025STENOCARE A/S reported Q2 2025 results showing net sales of DKK 1.7m, representing 131% year-over-year growth, driven primarily by increased sales in Denmark for its THC/CBD and new CBD100 oil products. The company achieved positive EBITDA of DKK 0.02m for the first time since Q1-19, supported by a 51% year-over-year reduction in operational expenses through its STENOCARE 3.0 strategy, which repositioned the company as a trading and product development business after exiting cultivation activities. The company's premium Astrum Oil product was launched in three countries (Germany, Australia, Norway) during Q1-25, providing additional growth potential as market penetration advances.CannabisbusinesstimesSolubility, Bioavailability, and the Future of Cannabis Consumption and PharmaceuticalsKenneth Morrow, founder of Trichome Technologies, argues that current cannabis beverages and edibles suffer from poor bioavailability due to the widespread use of inefficient micro- and nano-emulsions. He advocates for the adoption of superior soluble powder formulations and pharmaceutical-grade terpene isolates to improve consumer experience and prepare for future medical research. The article highlights specific advancements in formulation technology, such as Stenocare's Astrum oil and patented nebulizer delivery systems.